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Diacylglycerol lipase α knockout mice 
demonstrate metabolic and behavioral 
phenotypes similar to those of 
cannabinoid receptor 1 knockout mice
David R. Powell*, Jason P. Gay, Nathaniel Wilganowski, Deon Doree, 
Katerina V. Savelieva, Thomas H. Lanthorn, Robert Read, Peter Vogel, Gwenn M. Hansen, 
Robert Brommage, Zhi-Ming Ding, Urvi Desai, and Brian Zambrowicz
Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA
After creating >4,650 knockouts (KOs) of independent mouse genes, we screened them 
by high-throughput phenotyping and found that cannabinoid receptor 1 (Cnr1) KO mice 
had the same lean phenotype published by others. We asked if our KOs of DAG lipase α 
or β (Dagla or Daglb), which catalyze biosynthesis of the endocannabinoid (EC) 2-arachi-
donoylglycerol (2-AG), or Napepld, which catalyzes biosynthesis of the EC anandamide, 
shared the lean phenotype of Cnr1 KO mice. We found that Dagla KO mice, but not Daglb 
or Napepld KO mice, were among the leanest of 3651 chow-fed KO lines screened. In 
confirmatory studies, chow- or high fat diet-fed Dagla and Cnr1 KO mice were leaner than 
wild-type (WT) littermates; when data from multiple cohorts of adult mice were combined, 
body fat was 47 and 45% lower in Dagla and Cnr1 KO mice, respectively, relative to WT 
values. By contrast, neither Daglb nor Napepld KO mice were lean. Weanling Dagla KO 
mice ate less than WT mice and had body weight (BW) similar to pair-fed WT mice, and 
adult Dagla KO mice had normal activity and VO2 levels, similar to Cnr1 KO mice. Our Dagla 
and Cnr1 KO mice also had low fasting insulin, triglyceride, and total cholesterol levels, and 
after glucose challenge had normal glucose but very low insulin levels. Dagla and Cnr1 KO 
mice also showed similar responses to a battery of behavioral tests. These data suggest: 
(1) the lean phenotype of young Dagla and Cnr1 KO mice is mainly due to hypophagia; (2) 
in pathways where ECs signal through Cnr1 to regulate food intake and other metabolic 
and behavioral phenotypes observed in Cnr1 KO mice, Dagla alone provides the 2-AG that 
serves as the EC signal; and (3) small molecule Dagla inhibitors with a pharmacokinetic 
profile similar to that of Cnr1 inverse agonists are likely to mirror the ability of these Cnr1 
inverse agonists to lower BW and improve glycemic control in obese patients with type 2 
diabetes, but may also induce undesirable neuropsychiatric side-effects.
Keywords: mouse knockout models, diacylglycerol lipase gene, cannabinoid receptor 1 gene, obesity, 
endocannabinoids, 2-arachidonoylglycerol, anxiety, depression
introduction
There are an estimated 500 million obese people worldwide (1). This obesity epidemic is a major 
contributor to the dramatic increase in prevalence of type-2 diabetes (T2D) and the rise in diabetes 
complications (2). Unfortunately, efforts to induce weight loss by encouraging changes in dietary intake 
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and physical activity alone have not reversed the obesity epidemic; 
this suggests that combining these behavioral modifications with a 
safe and effective anti-obesity drug regimen is the approach most 
likely to result in meaningful and sustained loss of body fat (3). 
Although three new anti-obesity drugs were recently approved 
in the United States, each has significant safety issues that are 
being evaluated in post-marketing studies (3). There is a need for 
additional anti-obesity drugs to complement and/or replace those 
that are currently approved.
The endocannabinoid (EC) system has long been linked to the 
regulation of food intake and energy balance (4). The primary 
psychoactive cannabinoid, Δ9-tetrahydrocannabinol (THC), 
signals through the G-protein-coupled receptors Cnr1 and Cnr2, 
also known as CB1 and CB2, respectively (5). The two major 
endogenous ligands or ECs that signal through these receptors are 
2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine 
(AEA or anandamide). The final enzymatic step in the synthe-
sis of 2-AG is catalyzed by either diacylglycerol lipase α or β 
(Dagla or Daglb); by contrast, a number of enzymes, including 
N-acylphosphatidylethanolamine-hydrolyzing phospholipase D 
(Napepld), catalyze the final step in the synthesis of AEA (6–9). 
Cnr1 is highly and widely expressed in central nervous system 
(CNS) neurons, including neurons that regulate energy balance, 
and is also expressed in peripheral organs important for metabolic 
control; by contrast, Cnr2 is expressed primarily by cells involved 
in regulating immune function (10). Dagla is much more highly 
expressed in CNS neurons than in peripheral tissues with CNS 
expression mirroring that of Cnr1, Daglb is widely expressed but 
with much lower CNS expression than Dagla, and Napepld is 
widely expressed with highest expression in the CNS (6, 11). In the 
CNS, Dagla and Daglb demonstrate dendritic expression, consist-
ent with the model that ECs, and particularly 2-AG, produced 
by post-synaptic cells inhibit presynaptic release of excitatory 
or inhibitory neurotransmitters by signaling through Cnr1 on 
presynaptic terminals (6, 12).
Food intake can be stimulated by oral delivery of THC, and 
by injections of either 2-AG or AEA, and this effect is blocked by 
the Cnr1 inverse agonist rimonabant (13–16). Further evidence 
that Cnr1 mediates this feeding response is provided by studies 
showing that hypophagia and decreased body weight (BW) are 
found in Cnr1 knockout (KO) mice and in mice chronically treated 
with rimonabant (13, 17–21). Long-term rimonabant treatment 
induced weight loss not only in rodent models but also in obese 
humans studied in multiple clinical trials (22–24). Unfortunately, 
neuropsychiatric side-effects, which were likely on-target consid-
ering the role of ECs in neural pathways regulating a wide range of 
emotional behaviors, ultimately led to withdrawal of rimonabant 
from the market (24–26).
In an effort to identify potential drug targets, Lexicon 
Pharmaceuticals performed a high-throughput phenotypic screen 
on >4,650 KOs of independent genes encoding druggable proteins 
(27–31). As part of this phenotypic screen, body fat was measured 
in cohorts of chow-fed mice from 3,651 KO lines. Among KO 
lines identified with potential body fat phenotypes, Cnr1 KO 
mice had a lean phenotype, confirmed using additional cohorts 
of mice (30), that was consistent with the lean phenotype of Cnr1 
KO mice reported by others (17, 20). Although Dagla, Daglb, and 
Napepld KO lines have been generated (9, 32, 33), their body fat 
levels have not been reported. Because these three proteins are 
potentially druggable enzymes, Dagla, Daglb, and Napepld KO 
lines were phenotyped in our screen. We chose to review the 
screen results for body fat from these KO lines to determine if 
any or all shared the lean phenotype of Cnr1 KO mice, and if 
so to examine them in greater detail to determine how closely 
other phenotypic characteristics mirrored those of Cnr1 KO mice, 
including behavioral phenotypes that suggest the possibility of on-
target neuropsychiatric side-effects which would likely preclude 
developing inhibitors of these enzymes as anti-obesity drugs for 
humans.
Materials and Methods
generation of KO Mice
ApoE KO mice were obtained from Taconic (catalog no. APOE-M, 
Taconic Biosciences, Hudson, NY, USA). All other KO mice were 
generated at Lexicon Pharmaceuticals on a 129S5/SvEvBrd x 
C57BL/6-Tyrc-Brd hybrid background. Our approach to knocking 
out and phenotyping mouse orthologs of the potentially druggable 
genes in the human genome is published (27–31). Cnr1 KO, Dagla 
KO, Daglb KO, and Dagla/Daglb double KO (dagla/b DKO) mice 
have been described (30, 33). Mice heterozygous for both Dagla 
and ApoE were bred to generate Dagla/ApoE DKO mice. Napepld 
KO mice were generated by gene trapping; methods for gene 
trapping in embryonic stem cells, identifying trapped genes using 
OmniBank Sequence Tags, characterizing retroviral gene-trap 
vector insertion sites, and RT-PCR analysis of KO and wild-type 
(WT) transcripts are published (34). Briefly, a retroviral gene-trap 
vector was used to produce OmniBank clone OST429065, which 
contains an intron 3 insertion that truncates the Napepld gene 
product immediately after the second coding exon; this clone was 
used to generate Napepld KO mice (Figure S1 in Supplementary 
Material). Genotyping was performed on tail DNA as described 
previously (34).
Mouse care and study
All studies were performed in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The protocols for 
all studies were approved by the Lexicon Institutional Animal 
Care and Use Committee (OLAW Assurance Number, A4152-
01; AAALAC International Accreditation Number, 001025). 
General methods for mouse care have been described (34). 
Mice were fed either standard rodent chow (3.56  kcal/g; 9F 
5020, Purina, St Louis, MO, USA), low-fat diet (LFD) contain-
ing 10% kcal from fat (3.85 kcal/g; D12450B, Research Diets, 
New Brunswick, NJ, USA), high-fat diet (HFD) containing 45% 
kcal from fat (4.73 kcal/g; D12451, Research Diets), or western 
diet (4.7 kcal/g; D12079B; Research Diets). Pair-feeding and 
food consumption studies were performed as described previ-
ously (35).
Body composition Determinations
Body composition was measured using either dual energy x-ray 
absorptiometry (DEXA; PIXImus, InsideOutside Sales, Fitchburg, 
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WI, USA) or quantitative magnetic resonance (QMR, ECHO 
Medical Systems, Houston, TX, USA) technologies as described 
previously (30). For our phenotypic screen, body fat was analyzed 
on 14-week-old mice by DEXA and data presented as described 
previously (30). Briefly, for each KO line, mean KO % body fat/
mean WT littermate % body fat was calculated for both male 
and female mice, and then these male and female values were 
averaged, yielding a normalized % body fat value. For most KO 
lines, four male KO, two male WT, four female KO, and two 
female WT mice were analyzed. Lines with fewer than four KO 
mice or fewer than three WT mice were excluded. For lines with 
uneven distributions of male and female mice, values for the 
normalized % body fat calculation were weighted to take into 
account the actual number of mice analyzed. For X-linked lines, 
only male data were used.
stool analysis
Group-housed KO and WT mice were fed HFD containing green 
dye to aid in stool identification. Each cage of mice underwent 
24-h stool collections for three consecutive days. After each 24-h 
stool collection was weighed, lipids were extracted over 24 h using 
distilled acetone in a Soxhlet apparatus. After removal of residual 
acetone by evaporation, each stool collection was reweighed, with 
the difference in weights representing the amount of acetone-
extractable fat.
Measurements of Physical activity and VO2
Mice were individually placed in Oxymax chambers (Oxymax, 
Columbus Instruments, Columbus, OH, USA) and allowed to 
acclimate overnight. Starting at 10:00 a.m. the following day, 
each mouse had VO2 and physical activity measured over the 
next 24 h as described previously (35). Mice were also studied 
in a second system that measures physical activity, the ER-4000 
physiological measurement system (Mini Mitter, Bend, OR, USA). 
In these studies, mice first had E-mitter transponders surgically 
implanted into their peritoneal cavity; after a 3-day recovery 
period, mice were placed in individual cages within range of an 
ER-4000 receiver, which measures activity by sensing the strength 
of the signal received from the E-mitter. Activity data for each 
mouse were collected in 10 min intervals, and averaged per hour, 
for a period of 3  weeks using the VitalView Data Acquisition 
System (Mini Mitter).
Blood sample analysis
Unless stated otherwise, blood was obtained from fed mice by 
retro-orbital bleed and serum was assayed for glucose, total 
cholesterol, total triglycerides (TGs), alanine aminotransferase 
(ALT), and aspartate aminotransferase (AST) by Cobas Integra 400 
analyzer (Roche Diagnostics, Indianapolis, IN, USA) as described 
previously (34).
Oral glucose Tolerance Tests
Oral glucose tolerance tests (OGTTs) were performed on con-
scious, unanesthetized mice. After an overnight fast, mice were 
bled from the retro-orbital plexus at baseline and then received 
2 g/kg glucose by oral gavage. Whole-blood samples obtained from 
the retro-orbital plexus at 0, 30, and 60 min were directly assayed 
for glucose levels by ACCU-CHEK Aviva glucometer (Roche, 
Indianapolis, IN, USA); serum obtained at 0 and 30 min was used 
to measure insulin levels (Ultra Sensitive Rat Insulin ELISA Kit, 
Cat. 90060; Crystal Chem, Downers Grove, IL, USA).
Pathology
Livers obtained from 20- to 24-week-old WT, Dagla KO, ApoE KO, 
and Dagla/ApoE DKO littermate mice fed western diet since wean-
ing were prepared for histopathologic examination as described 
previously (35). Liver sections were interspersed during reading 
by a pathologist to reduce bias, and were given semi quantitative 
scores of 0–4, without knowledge of genotype, for degree and extent 
of fatty cytoplasmic vacuolation (steatosis) and for number and 
extent of small histiocytic and mixed inflammatory foci replacing 
hepatic parenchyma (inflammation) (36).
Behavioral Testing
Dagla and Cnr1 KO mice were studied in tail suspension and 
forced swim tests developed to screen antidepressant compounds 
(37), open field and platform tests developed to screen anxiolytic 
compounds (38), the hot plate test used to assess nociceptive pain 
(39), and the marble burying test used to screen compounds for 
possible effects on anxiety, depression, and the repetitive behavior 
of obsessive compulsive disorder (40). Our protocols for tail sus-
pension, forced swim, open field, marble burying, and hot plate 
tests are published (41), as is our protocol for the platform test (38).
statistics
Data are presented as mean ± SD. Unless stated otherwise, com-
parisons between two groups were analyzed by unpaired Student’s 
t-test, and comparisons among three or more groups were analyzed 
by one-way ANOVA, with post hoc analysis performed using the 
Bonferroni correction. For all behavioral tests, for body fat analysis 
from the Dagla/b DKO study, and for liver histopathology and body 
composition analyses from the Dagla/ApoE DKO study, two-way 
ANOVA was employed. All statistical tests were performed using 
PRISM 4.03 (GraphPad). Differences were considered statistically 
significant when P < 0.05.
results
Similar to Cnr1 KO mice, Dagla KO mice were lean relative to WT 
littermates in our high-throughput phenotypic screen of 3,651 
KO lines maintained on chow diet; by contrast, neither Daglb nor 
Napepld KO mice were lean in this screen (Figure 1A). Dagla mice 
had normal Mendelian distribution at weaning (923 WT, 1882 Het, 
971 KO) and appeared healthy, similar to Cnr1 (378 WT, 717 Het, 
318 KO), Daglb (173 WT, 332 Het, 169 KO), and Napepld (77 WT, 
150 Het, 82 KO) mice. To confirm the lean phenotype observed 
during screening, additional cohorts of chow-fed male and female 
Dagla KO mice were studied and were found to have significantly 
decreased BW, body fat, and lean body mass (LBM) at weaning 
and through 20 weeks of age (Figures 1B,C).
Dagla KO mice fed HFD from weaning developed significantly 
decreased BW, body fat, and LBM relative to WT littermates 
(Figures  2A,B). When we combined QMR data obtained at 
15–17 weeks of age from multiple chow- and HFD-fed cohorts, 
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we found that BW, body fat, and LBM were significantly 
decreased by 21, 47, and 11%, respectively, in 131 Dagla KO 
mice compared to 169 WT littermates (Figures 2C–E; Table S1 
in Supplementary Material); because normalized data from male 
and female KO mice were comparable, they were combined for 
this analysis. The lean phenotype persisted with age, and was still 
present in Dagla KO mice aged more than 1 year (Table 1). The 
body composition phenotype of Dagla KO mice was confirmed 
by DEXA analysis (Table S2 in Supplementary Material), which 
also revealed a slightly decreased bone mass for 29-week-old 
Dagla KO mice that was probably appropriate for their slightly 
smaller skeletal frame as demonstrated by femur length measure-
ments (Figure  2F). The lean phenotype of Dagla KO mice is 
quite similar to that observed in our Cnr1 KO mice (30). In 
an update of our Cnr1 KO data, we combined QMR measure-
ments obtained at 16–32 weeks of age from multiple chow- and 
HFD-fed cohorts and found that BW, body fat, and LBM were 
significantly decreased by 18, 45, and 8%, respectively, in 80 
Cnr1 KO mice compared to 102 WT littermates (Figures 3A–C; 
Table S3 in Supplementary Material); because normalized data 
from these male and female KO mice were comparable, they 
were combined for this analysis. By contrast, neither Napepld 
nor Daglb KO mice raised on HFD showed decreased body fat 
at 15 weeks of age (Figures 3D,E). In addition, DAGLa/b DKO 
mice showed no enhancement of the low body fat phenotype 
over that observed in DAGLa KO mice (Figure 3F); these mice 
Figure 1 | chow-fed Dagla KO mice are lean. (a) Histogram of 
normalized% body fat for 3,651 knockout lines maintained on chow diet. 
Body composition analyses performed by DEXA on 14-week-old male mice 
fed chow diet from weaning were used to calculate normalized % body fat for 
each knockout line as described in Materials and Methods. The mean 
normalized % body fat value was 1.08 ± 0.15; the distribution was normal 
based on Kolmogorov–Smirnov testing (P < 0.01). Solid points indicate 
actual numbers of knockout lines. Curved line shows the calculated curve; 
the range for 1 and 2 SD from the mean are indicated by lines located below 
the curve, and values for Cnr1, Dagla, Daglb, and Napepld KO mice are 
indicated by lines shown above the curve. (B) Time course for body weight 
of chow-fed Dagla KO mice and their WT littermates. (c) Time course for 
body fat measured by QMR of chow-fed Dagla KO mice and their WT 
littermates. For each data point in (B,c), N = 7–15 mice. KO mice different 
from WT mice of the same age and gender, *P < 0.05, **P < 0.01, 
***P < 0.001.
appeared healthy at weaning, and their Mendelian distribution 
was normal.
We sought to identify the mechanism behind the low-body 
fat phenotype of Dagla KO mice. We found that Dagla KO mice 
ate significantly less than WT littermates at weaning (Figure 4A), 
similar to Cnr1 KO mice (Figure  4B). A pair-feeding study, 
performed on female Dagla mice beginning at weaning, showed 
that pair-fed WT mice had BWs similar to Dagla KO mice and 
significantly less than WT mice fed ad lib (Figure 4C), suggesting 
that the lean phenotype of Dagla KO mice at weaning was primar-
ily due to decreased food intake. By contrast, when we studied 
27-week-old Dagla KO mice with an established lean phenotype, 
we found that WT littermates pair-fed to these Dagla KO mice 
showed an insignificant loss of BW relative to WT littermates that 
were fed ad lib (Figure 4D). Adult Dagla KO mice did not show 
evidence of malabsorption (Figures 5A,B) and, in addition, had 
VO2 (Figure 5C) and total activity (Figure 5D) levels that were not 
different from those of WT littermate controls. The total activity 
data were confirmed using a different technology in a separate 
cohort (Figure 5E). Similar to Dagla KO mice, Cnr1 KO mice had 
total activity levels that were comparable to levels of WT littermates 
(Figure 5F).
We evaluated the effect of Dagla deficiency on metabolic 
parameters. Although Dagla KO mice maintained on HFD had 
fasting blood glucose levels that were not different from WT, and 
responded to an OGTT with only modest lowering of glucose 
Figure 2 | Dagla KO mice are lean on various diets. (a) Time course for 
body weight of Dagla KO mice and their WT littermates fed HFD. (B) Time 
course for body fat measured by QMR of Dagla KO mice and their WT 
littermates fed HFD. For (a,B), N = 12–15 mice for each data point. 
Normalized data for (c) body weight, (D) body fat measured by QMR, and  
(e) LBM measured by QMR on 16-week-old Dagla KO mice (N = 131) and 
their WT littermates (N = 169) fed various diets. (F). Length of femurs from 
Dagla KO mice (N = 8 males and 6 females) and their WT littermates (N = 9 
males and 8 females). KO mice different from WT mice of the same age and 
gender, *P < 0.05, **P < 0.01, ***P < 0.001.
TaBle 1 | Body composition by QMr of Dagla KO and WT mice at >1 year of age.
cohort genotype  N age (months) Body weight (g) Body fat (g) % Body fat lBM (g)
2-M WT 9 14 55.8 ± 8.4 19.8 ± 4.8 35.0 ± 5.5 36.0 ± 4.5
2-M KO 6 14 41.9 ± 5.8* 13.1 ± 6.1* 35.0 ± 7.3 28.8 ± 4.2**
2-F WT 6 14 35.8 ± 7.7 11.1 ± 7.4 29.0 ± 12.9 24.7 ± 2.6
2-F KO 7 14 24.5 ± 2.1** 3.9 ± 0.7* 16.0 ± 1.9* 20.6 ± 1.7**
3-M WF 10 14 55.1 ± 6.5 21.1 ± 4.5 37.9 ± 4.1 34.0 ± 2.5
3-M KO 8 14 34.3 ± 6.9*** 8.6 ± 4.6*** 23.7 ± 8.0*** 25.7 ± 2.5***
3-F WF 10 15 40.5 ± 9.4 15.4 ± 7.7 36.3 ± 9.5 25.1 ± 2.4
3-F KO 6 15 26.3 ± 4.2** 6.0 ± 1.3* 22.9 ± 2.7** 20.3 ± 3.2**
8-F WT 7 15 42.4 ± 9.3 16.8 ± 7.4 38.0 ± 9.7 25.6 ± 2.3
8-F KO 7 15 26.8 ± 2.9** 5.1 ± 1.5** 18.7 ± 3.8*** 21.7 ± 1.7**
Data presented as mean ± SD; N = number of mice; M = male; F = female; LBM, lean body mass. KO different from WF, *P < 0.05; **P < 0.01; ***P < 0.001.
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excursions relative to WT values, they did exhibit significantly 
lower 0 and 30 min insulin levels (Figures 6A–D); thus, less insulin 
was required to maintain post-prandial glucose excursions in 
these non-diabetic mice. Cnr1 KO mice maintained on HFD also 
showed no difference from WT mice in terms of fasting blood 
glucose and, during OGTTs, exhibited an insignificant improve-
ment in glucose excursions associated with significantly lower 0 
and 30 min insulin levels (Figures 6E,F). Fasting TG and total 
appeared healthy at weaning, and their Mendelian distribution 
was normal.
We sought to identify the mechanism behind the low-body 
fat phenotype of Dagla KO mice. We found that Dagla KO mice 
ate significantly less than WT littermates at weaning (Figure 4A), 
similar to Cnr1 KO mice (Figure  4B). A pair-feeding study, 
performed on female Dagla mice beginning at weaning, showed 
that pair-fed WT mice had BWs similar to Dagla KO mice and 
significantly less than WT mice fed ad lib (Figure 4C), suggesting 
that the lean phenotype of Dagla KO mice at weaning was primar-
ily due to decreased food intake. By contrast, when we studied 
27-week-old Dagla KO mice with an established lean phenotype, 
we found that WT littermates pair-fed to these Dagla KO mice 
showed an insignificant loss of BW relative to WT littermates that 
were fed ad lib (Figure 4D). Adult Dagla KO mice did not show 
evidence of malabsorption (Figures 5A,B) and, in addition, had 
VO2 (Figure 5C) and total activity (Figure 5D) levels that were not 
different from those of WT littermate controls. The total activity 
data were confirmed using a different technology in a separate 
cohort (Figure 5E). Similar to Dagla KO mice, Cnr1 KO mice had 
total activity levels that were comparable to levels of WT littermates 
(Figure 5F).
We evaluated the effect of Dagla deficiency on metabolic 
parameters. Although Dagla KO mice maintained on HFD had 
fasting blood glucose levels that were not different from WT, and 
responded to an OGTT with only modest lowering of glucose 
Figure 2 | Dagla KO mice are lean on various diets. (a) Time course for 
body weight of Dagla KO mice and their WT littermates fed HFD. (B) Time 
course for body fat measured by QMR of Dagla KO mice and their WT 
littermates fed HFD. For (a,B), N = 12–15 mice for each data point. 
Normalized data for (c) body weight, (D) body fat measured by QMR, and  
(e) LBM measured by QMR on 16-week-old Dagla KO mice (N = 131) and 
their WT littermates (N = 169) fed various diets. (F). Length of femurs from 
Dagla KO mice (N = 8 males and 6 females) and their WT littermates (N = 9 
males and 8 females). KO mice different from WT mice of the same age and 
gender, *P < 0.05, **P < 0.01, ***P < 0.001.
TaBle 1 | Body composition by QMr of Dagla KO and WT mice at >1 year of age.
cohort genotype  N age (months) Body weight (g) Body fat (g) % Body fat lBM (g)
2-M WT 9 14 55.8 ± 8.4 19.8 ± 4.8 35.0 ± 5.5 36.0 ± 4.5
2-M KO 6 14 41.9 ± 5.8* 13.1 ± 6.1* 35.0 ± 7.3 28.8 ± 4.2**
2-F WT 6 14 35.8 ± 7.7 11.1 ± 7.4 29.0 ± 12.9 24.7 ± 2.6
2-F KO 7 14 24.5 ± 2.1** 3.9 ± 0.7* 16.0 ± 1.9* 20.6 ± 1.7**
3-M WF 10 14 55.1 ± 6.5 21.1 ± 4.5 37.9 ± 4.1 34.0 ± 2.5
3-M KO 8 14 34.3 ± 6.9*** 8.6 ± 4.6*** 23.7 ± 8.0*** 25.7 ± 2.5***
3-F WF 10 15 40.5 ± 9.4 15.4 ± 7.7 36.3 ± 9.5 25.1 ± 2.4
3-F KO 6 15 26.3 ± 4.2** 6.0 ± 1.3* 22.9 ± 2.7** 20.3 ± 3.2**
8-F WT 7 15 42.4 ± 9.3 16.8 ± 7.4 38.0 ± 9.7 25.6 ± 2.3
8-F KO 7 15 26.8 ± 2.9** 5.1 ± 1.5** 18.7 ± 3.8*** 21.7 ± 1.7**
Data presented as mean ± SD; N = number of mice; M = male; F = female; LBM, lean body mass. KO different from WF, *P < 0.05; **P < 0.01; ***P < 0.001.
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cholesterol levels tended to be lower in multiple cohorts of Dagla 
KO mice-fed HFD (Table S4 in Supplementary Material); when 
data were normalized such that mean WT values for each male and 
female cohort were assigned a value of 100%, and all data were then 
combined, TG and total cholesterol levels were significantly lower 
in Dagla KO mice, measuring 75 and 87% of WT littermate values, 
respectively (Figure 6G). Cnr1 KO mice weaned onto HFD showed 
a similar pattern (Table S4 in Supplementary Material); when data 
were again normalized and combined, TG and total cholesterol 
levels were significantly lower in Cnr1 KO mice, measuring 83 and 
80% of WT littermate values, respectively (Figure 6H). We also 
studied whether Dagla deficiency would protect against hepatic 
steatosis and inflammation by placing Dagla KO mice, ApoE KO 
mice, Dagla/ApoE DKO mice, and WT littermates on Western 
diet from weaning (Table 2). When these mice were studied at 
20–24 weeks of age, Dagla but not ApoE KO mice were lean relative 
to WT littermates, and histologic examination of hepatic tissue 
demonstrated that Dagla deficiency significantly protected WT 
mice from steatosis but not inflammation, whereas ApoE deficiency 
had no effect on either parameter in this analysis. Serum analysis 
showed that ApoE KO mice had increased TG, total cholesterol, 
and AST relative to WT littermates, and that the addition of Dagla 
deficiency to ApoE deficiency significantly lowered each of these 
parameters. Comparable studies were not performed using Cnr1 
KO mice.
Dagla and Cnr1 KO mice were also evaluated for their perfor-
mance during a number of behavioral tests (Table 3). During the 
tail suspension test, neither Dagla nor Cnr1 KO mice showed a 
significant difference in immobility time relative to WT littermates. 
The forced swim test showed significantly decreased immobility 
time in Dagla KO mice, while a much smaller cohort of Cnr1 KO 
mice showed a strong trend (P = 0.07) toward a similar decrease. 
In the open-field test, neither Dagla nor Cnr1 KO mice differed 
from WT littermates in total distance traveled, and both showed 
significantly less rearing activity than did their WT controls; by 
contrast, the Cnr1 KO mice spent significantly less time than WT 
Figure 3 | Presence of a lean phenotype in Cnr1 KO mice but not 
Napepld or Daglb KO mice. Normalized data for (a) body weight,  
(B) body fat measured by QMR and (c) LBM measured by QMR on  
16- to 32-week-old Cnr1 KO mice (N = 80) and their WT littermates 
(N = 102). (D) Body fat measured by QMR on 8 male Napepld KO mice 
and 8 male WT littermates at 12 weeks of age. (e) Normalized body fat 
measured by QMR on 61 Daglb KO mice and 54 WT littermates at 
15–16 weeks of age. For (a–e), KO mice different from WT mice, 
***P < 0.001. (F) Time course for body fat measured by QMR on female 
Dagla KO, Daglb KO, Dagla/b DKO, and WT littermates (N = 6–8 mice/
group). When analyzed by one-way ANOVA, different from Dagla KO and 
DKO mice, *P < 0.05, ***P < 0.001. When analyzed by two-way ANOVA, 
Dagla KO mice different from WT mice, P < 0.001; there was no interaction 
between Dagla KO and Daglb KO on body fat.
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littermates in the center of the open field, whereas Dagla KO and 
WT littermates were not different for this parameter. This last 
finding was revisited in the platform test, which provides a more 
specific measure of anxiety-related behavior (38); Dagla KO mice 
spent significantly more time than WT mice in the lighted area, 
and a much smaller cohort of Cnr1 KO and WT mice did not differ 
significantly for this parameter. Finally, both Dagla and Cnr1 KO 
mice buried significantly fewer marbles during the marble burying 
test, and both took significantly longer than their WT littermate 
controls to respond to a thermal stimulus during the hot plate test. 
For all tests except the marble burying in Dagla KO mice, and the 
forced swim and platform tests in Cnr1 KO mice, the findings in 
Table 3 were confirmed with at least one additional independent 
cohort of mice (data not shown).
Long-term survival was significantly decreased in Dagla KO 
mice (Figure 7). Despite this impaired survival, aging Dagla KO 
mice appeared healthy. In a cohort of 12 Dagla KO mice that 
were at least 1 year of age at necropsy, no pathological changes 
were noted in brain, heart, or other tissues examined that could 
explain the decreased survival of these mice (data not shown). 
On three separate occasions, Dagla KO mice undergoing QMR 
were observed to have spontaneous seizure activity and none 
of these mice survived the seizure episode, suggesting that the 
decreased survival was related to an underlying neurological 
abnormality which was not evident during histopathologic 
analysis of brain tissue.
Figure 4 | Decreased food intake by Dagla and Cnr1 KO mice at 
weaning. (a) Intake of HFD by Dagla male mice (three mice/cage, five 
cages/genotype). (B) Intake of HFD by Cnr1 male mice (two to three 
mice/cage, five cages/genotype). For (a,B), KO mice different from WT 
mice, *P < 0.05, **P < 0.01, ***P < 0.001. (c) Body weights of ad lib-fed 
Dagla KO mice, ad lib-fed WT littermate mice (WT-AL), and WT littermate 
mice that were pair-fed to the Dagla KO mice (WT-PF). Mice were 
individually housed weanling female littermates fed LFD; seven mice/
group. KO mice different from WT-AL mice, *P < 0.05, **P < 0.01; WT-PF 
mice different from WT-AL mice, ^P < 0.05. (D) Body weights of ad 
lib-fed Dagla KO mice, ad lib-fed WT littermate mice (WT-AL), and WT 
littermate mice that were pair-fed to the Dagla KO mice (WT-PF). All mice 
were individually housed 27-week-old male littermates fed HFD; seven 
mice/group.
Discussion
Our Dagla and Cnr1 KO mice share the same lean phenotype 
when raised on either chow or HFD. In fact, the similarity of 
their lean phenotypes was remarkable, with body fat 47 and 45% 
lower in Dagla and Cnr1 KO mice, respectively, relative to WT 
littermates. By contrast, Daglb and Napepld KO mice had normal 
body fat stores. The lean phenotype of our Cnr1 KO mice confirms 
published data (17, 20, 30). By contrast, body fat data have not 
been reported for Dagla or Daglb KO mice, although one study 
did report that BW was significantly decreased in Dagla KO mice 
and slightly decreased in Daglb KO mice (32). The absence of a 
body composition phenotype in Napepld KO mice is consistent 
with recent data indicating that this enzyme is not required for 
maintenance of normal CNS AEA levels (9). We also found that 
Dagla and Cnr1 KO mice are hypophagic, consistent with past 
studies showing decreased feeding behavior in Cnr1 KO mice (17, 
18, 20). In our studies, decreased food intake was demonstrated 
in weanling Dagla and Cnr1 KO mice at a time when their lean 
phenotype was developing. In addition, a pair-feeding study 
performed in weanling Dagla KO mice showed that hypophagia 
was the mechanism behind their lean phenotype, a result identical 
to that reported for a pair-feeding study of weanling Cnr1 KO mice 
(17). The important role of hypophagia in development of the 
lean phenotype in Dagla and Cnr1 KO mice suggests that the lean 
phenotype results primarily from loss of Dagla-generated 2-AG 
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signaling through Cnr1 expressed by CNS rather than by periph-
eral tissues. This hypothesis is consistent with the observations 
that: (1) Cnr1 and Dagla are most highly expressed in the CNS, 
(2) brain 2-AG levels are much lower in Dagla KO mice compared 
to Daglb KO mice, and (3) removal of Cnr1 from neurons known 
to regulate energy balance, but not from non-neuronal peripheral 
tissues, is all that is required to reproduce the lean phenotype 
observed in global Cnr1 KO mice [(32, 33, 42, 43); our unpublished 
observations]. Interestingly, hypophagia was not as pronounced 
in older Dagla KO mice, and in fact pair-feeding of WT mice to 
Dagla KO mice was not associated with marked loss of BW relative 
to ad lib-fed WT littermates, a finding that exactly reproduced 
results reported for pair-feeding studies using older Cnr1 KO 
mice (17). Such results may simply reflect increased food intake 
as an adaptation to maintain already depleted body fat stores and 
LBM in adult Dagla and Cnr1 KO mice, or they could suggest that 
food intake-independent mechanisms were operative in adult KO 
mice. However, activity was not increased in either our adult Dagla 
Figure 5 | Fecal weight, fecal fat and VO2 of Dagla KO mice, and 
activity levels of Dagla and Cnr1 KO mice. Fecal weight (a) and fecal fat 
(B) from HFD-fed, 8-week-old group-housed male Dagla KO (four cages) and 
WT littermate (five cages) mice; mice were housed three per cage. VO2(c) and 
total activity (D) levels of HFD-fed, 45-week-old female Dagla KO mice (N = 6) 
and their WT littermates (N = 8) measured in Oxymax chambers over 24 h as 
described in the Section “Materials and Methods.” (e) Total activity levels of 
HFD-fed, 30-week-old male Dagla KO mice (N = 9) and their WT littermates 
(N = 7), and (F) activity levels of HFD-fed, 30-week-old male Cnr1 KO mice 
(N = 5) and their WT littermates (N = 6), measured over 3 weeks in the 
ER-4000 physiological measurement system as described in the Section 
“Materials and Methods.”
or Cnr1 KO mice in three independent assays and there was no 
evidence of malabsorption in our Dagla KO mice. Also, VO2 was 
not increased in our Dagla KO mice or in Cnr1 KO mice studied by 
others (17); however, the error inherent in the indirect calorimetry 
method and the ability of Cnr1 inverse agonists to increase energy 
expenditure in rodents and humans (44, 45) suggest that additional 
studies are needed to determine if increased energy expenditure 
contributes to the lean phenotype of older Dagla KO mice.
A number of metabolic parameters were studied in Dagla and 
Cnr1 KO mice. Neither HFD-fed Dagla nor Cnr1 KO mice showed 
consistent improvements in fasting blood glucose levels or glucose 
excursions during OGTTs, but both KOs had significantly lower 
insulin levels during a fast and 30 min after glucose challenge, along 
with lower triglyceride (TG) and total cholesterol levels. These 
results are similar to Cnr1 KO mouse data published by others (20, 
42, 43, 46). Dagla KO mice-fed western diet also showed a decrease 
in hepatic steatosis, which mirrored their decrease in total body 
fat. Past studies initially suggested that hepatic Cnr1 deficiency 
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alone prevented the HFD-induced development of hepatic stea-
tosis, insulin resistance, and dyslipidemia, whereas extra-hepatic 
Cnr1 deficiency was required to prevent HFD-induced obesity 
(46). Although subsequent studies reported that CNS-specific 
Cnr1 deficiency alone prevented HFD-induced hepatic steatosis, 
insulin resistance, and dyslipidemia (42, 43), recent data indicate 
that peripherally restricted Cnr1 antagonists can indeed prevent 
this metabolic syndrome (47). Our data suggest that, wherever the 
Figure 6 | improved OgTT and fasting serum lipid measurements in 
Dagla and Cnr1 KO mice. (a) Glucose excursions, and (B) 0 and 30 min 
insulin levels, from an OGTT performed on HFD-fed male Dagla KO mice 
(N = 12) and their WT littermates (N = 14) at 16 weeks of age. (c) Glucose 
excursions, and (D) 0 and 30 min insulin levels, from an OGTT performed on 
and independent cohort of HFD-fed male Dagla KO mice (N = 10) and their WT 
littermates (N = 6) at 18 weeks of age. (e) Glucose excursions, and (F) 0 and 
30 min insulin levels, from an OGTT performed on HFD-fed male Cnr1 KO mice 
(N = 14) and their WT littermates (N = 15) at 16 weeks of age. For (a–F) 
above, KO glucose AUC and insulin levels different from WT, *P < 0.05, 
**P < 0.01. Normalized fasting serum triglyceride and total cholesterol levels 
from (g) adult Dagla KO mice (N = 47) and their WT littermates (N = 70), and 
(h) adult Cnr1 KO mice (N = 21) and their WT littermates (N = 26); KO different 
from WT, ***P < 0.001.
Cnr1 that confers each of these effects is expressed, Dagla must 
also be expressed to provide the 2-AG that serves as the EC signal.
Mice treated with rimonabant show the same resistance to 
hepatic steatosis, insulin resistance, dyslipidemia, and obesity as do 
mice lacking Cnr1 (19, 20, 42, 43, 46, 48) or Dagla (data presented 
here), suggesting that Dagla inhibitors may achieve the same effects 
as Cnr1 inverse agonists if delivered to the right location. In obese 
humans with T2D, rimonabant significantly lowered BW, A1C, 
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insulin resistance, and serum TGs (22, 49), suggesting that Dagla 
inhibitors will also be effective in these individuals. Of the few 
Dagla inhibitors studied, the most promising data are for O-7460, 
a small molecule that lowered food intake in a dose-dependent 
manner during the 14 h after a single intraperitoneal injection; the 
highest dose was associated with slight but significant decreases in 
BW and hypothalamic 2-AG levels (50). Unfortunately, hypophagia 
is a common sign of off-target toxicity for many compounds. For 
this reason, developers of the Cnr1 inverse agonists, rimonabant 
and taranabant, demonstrated that their compounds lowered food 
TaBle 2 | serum lipids, liver function/steatosis, and body fat in Dagla 
KO, apoe KO, and Dagla/apoe DKO mice-fed Western diet.
WT Dagla KO ApoE KO D/A DKO
ALT, U/L 136 ± 107 (19) 137 ± 98 (13) 124 ± 94 (17) 43 ± 35 (10)
AST, U/L 87 ± 72 (19)*** 83 ± 23 (13)** 176 ± 85 (17) 90 ± 49 (10)*
TG, mg/dL 82 ± 17 (19)*** 84 ± 15 (13)*** 308 ± 153 (17) 171 ± 71 (10)**
Chol, mg/dL 220 ± 76 (19)*** 173 ± 59 (13)*** 1713 ± 621 (17) 823 ± 759 (10)***
Body fata, g 14.7 ± 4.2 (19) 8.3 ± 3.7 (13)∧∧∧ 13.4 ± 5.5 (17) 6.7 ± 4.1 (10)
Liver steatosisb 2.9 ± 1.5 (5) 1.3 ± 1.0 (11)∧∧∧ 2.8 ± 0.5 (7) 1.4 ± 1.0 (7)
Liver 
inflammationc
1.2 ± 1.2 (5) 0.8 ± 0.8 (7) 2.0 ± 0.5 (11) 1.6 ± 0.8 (7)
N, number of mice; TG, triglyceride; Chol, total cholesterol; D/A DKO, Dagla/ApoE 
double KO mice. All serum samples obtained from fed female mice at 20–24 weeks of 
age. 
aBody fat measured by QMR at 20–24 weeks of age.
bLiver steatosis score in semi quantitative units (see Materials and Methods); higher 
value suggests more steatosis.
cLiver inflammation score in semi quantitative units (see Materials and Methods): higher 
value suggests more inflammation.
Different from WT by two-way ANOVA, ∧∧∧P < 0.001. Different from ApoE KO by  
one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001.
TaBle 3 | Behavioral studies in Dagla and Cnr1 KO mice.
Dagla Cnr1
Test WT       KO       WT       KO
Tail suspension
Immobility 
time, s
104 ± 40 (21) 129 ± 64 (16) 76 ± 42 (24) 94 ± 56 (20)
Forced swim
Immobility 
time, s
237 ± 66 (25) 123 ± 86 (17)*** 168 ± 77 (8) 84 ± 78 (6)
Open field
Total distance, 
 cm
2244 ± 783 (26) 2138 ± 766 (I8) 1724 ± 917 (25) 1265 ± 855 (24)
Time in  
center, s
313 ± 117 (26) 267 ± 193 (18) 346 ± 198 (25) 147 ± 108 (24)***
Rearing, N 51 ± 25 (26) 29 ± 26 (18)** 50 ± 43 (25) 13 ± 18 (24)***
Platform
Time in  
light, s
75 ± 68 (26) 187 ± 77 (17)*** 108 ± 97 (8) 70 ± 100 (7)
hot plate
Latency to  
respond, s
10.6 ± 3.6 (26) 15.3 ± 5.3 (18)** 8.6 ± 3.5 (25) 10.9 ± 3.9 (24)*
Marble burying
Marbles 
buried, N
13 ± 7 (26) 6 ± 7 (18)** 10 ± 7 (25) 4 ± 5 (24)***
N, number of mice; s, seconds. Different from WT, *P < 0.05, **P < 0.01, ***P < 0.001. 
Note: Cnr1 forced swim and platform tests were analyzed by Student’s t-test because 
only female mice were studied. In all other groups, two-way ANOVA showed no 
gender × genotype interaction, so male and female data were combined.
intake in WT but not Cnr1 KO mice (19, 51). Dagla inhibitors 
should also be tested in Dagla KO mice early in preclinical develop-
ment to confirm that their effects on food intake are truly on-target.
The EC system plays an important role in regulating emotional 
behavior (26). Although the Cnr1 inverse agonist rimonabant was 
an effective anti-obesity agent, it was often associated with affective 
disturbances such as anxiety and depression that made it unsuitable 
for routine use (22, 24, 25). The value of Dagla as an anti-obesity 
target would be enhanced if the favorable metabolic phenotype 
shared by Dagla and Cnr1 KO mice was not linked to the undesir-
able neuropsychiatric effects associated with rimonabant. For this 
reason, we chose to evaluate Dagla and Cnr1 KO mice in a series of 
tests designed to evaluate anxiety, depression, and other behaviors. 
Interestingly, published studies that used these behavioral tests 
to evaluate Cnr1 KO mice, or WT mice treated with compounds 
that modulate Cnr1 signaling, reported results that were often 
inconsistent with each other and with data we collected on our 
Cnr1 KO mice (39, 40, 52–61). This suggested that the value in 
our behavioral screen would come from directly comparing the 
behavioral phenotypes of Dagla and Cnr1 KO mice obtained in 
our laboratory. We found that Dagla and Cnr1 KO mice differed 
only in the open-field time in center and the platform tests, two 
related tests that use the same open-field chamber; here Dagla KO 
mice exhibited a more anxiolytic behavior. Dagla and Cnr1 KO 
mice showed similar behaviors in the hot plate, marble burying, 
open-field rearing, forced swim, open-field distance traveled, and 
tail suspension tests; for the first four of these tests, the behavior 
of KO mice from both lines appeared different from WT. The 
fact that both Dagla and Cnr1 KO mice responded similarly in 
most of the tests suggests that the 2-AG synthesized by Dagla is 
mediating not only effects on pathways regulating food intake 
and various metabolic parameters but also effects on pathways 
that influence important neuropsychiatric behaviors. Our studies 
were limited by the fact that we only employed a few acute assays 
to assess depression and anxiety (62). In addition, the open-field 
time in center and platform tests suggest the possibility that the 
two KO lines may differ in anxiety-related behavior, with Dagla 
KO mice exhibiting a more anxiolytic response; this is a potentially 
important finding, because it raises the possibility that Dagla KO 
mice do not share an undesirable behavioral phenotype present 
Figure 7 | Decreased survival of Dagla KO mice. Survival curves of 
combined male and female Dagla KO mice and their WT littermates from 
weaning through 41 weeks of age. KO different from WT, ***P < 0.001.
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in Cnr1 KO mice. Additional studies are therefore needed; if they 
ultimately confirm our overall impression that Dagla and Cnr1 KO 
mice share behavioral phenotypes, the response to Dagla inhibitors 
may well be similar to the response to Cnr1 antagonists and inverse 
agonists for both metabolic and neuropsychiatric effects. Finally, 
we observed seizure activity followed by death in three Dagla KO 
mice; this may explain the decreased survival of our Dagla KO line, 
which occurs despite a lack of histopathologic findings. Although 
we did not assess survival of our Cnr1 KO mice, others reported 
increased seizure activity and decreased survival without an obvi-
ous cause of death in Cnr1 KO mice (21). These shared findings 
provide further evidence for a close interaction between Dagla and 
Cnr1 in the normal regulation of multiple neurologic pathways.
Our high-throughput phenotypic screen correctly identified 
the lean phenotypes of Cnr1 and Dagla KO mice, just as it cor-
rectly identified the body fat phenotype of many KO lines in past 
studies; some of these KOs share their phenotype with humans 
having inactivating mutations in the same gene (30, 35, 63). Our 
screen has also identified genes that play a key role in regulating 
bone mass (31). Continued mining of our KO data, and KO data 
generated by the International Mouse Knockout Consortium, 
should identify genes that, when mutated, (1) result in specific 
diseases and (2) can be targeted to develop therapeutics for obesity, 
diabetes, osteoporosis, and other indications.
In summary, our data suggest that, in pathways where ECs signal 
through Cnr1 to regulate food intake, certain other behaviors and 
also other aspects of the metabolic phenotype observed in Cnr1 
KO mice, Dagla alone provides the 2-AG that serves as the EC 
signal. Based on these data, small molecule Dagla inhibitors with a 
pharmacokinetic profile similar to that of Cnr1 inverse agonists are 
likely to mirror the ability of these inverse agonists to decrease food 
intake, BW, TGs, and insulin resistance while improving glycemic 
control in obese patients with diabetes. Whether Dagla inhibitors 
will also be associated with undesirable neuropsychiatric events 
similar to those observed with use of Cnr1 inverse agonists, which 
must be considered possible based on data presented here, can 
only be answered with human clinical trials.
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